Smiling woman sitting in front of green wall at AlkermesSmiling woman sitting in front of green wall at AlkermesBlue Triangle graphic

News and Events

Sharing Stories of
Patients, Employees
and Communities

Featured News

May 09, 2022

Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Read more

May 02, 2022

Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month

Read more

April 27, 2022

Alkermes plc Reports First Quarter 2022 Financial Results

Read more

See all press releases

Our Commitment to Responsibility

Corporate responsibility has always played a central role in our business and has proven even more critical during the past year as we faced some of the most pressing public health and societal issues of our time – a dynamic global pandemic, systemic racism in the U.S. and around the world, and a worsening climate change crisis. Guided by our purpose and values, we took actions to respond to these critical issues, while sharpening our focus on scientific and business excellence in our efforts to help people living with complex and difficult-to-treat diseases. Our most recent Corporate Responsibility Report expounds on these efforts.

Corporate Responsibility Reports   

Our Stories


Each endeavor at Alkermes starts with collaboration and our shared commitment to make a difference for patients and our communitiesThese stories – which highlight our people, science and innovation, and leadership perspectives – showcase just a subset of what makes us proud to be part of Alkermes. Visit our full gallery of stories by clicking on the link below.

Portrait of employee standing masked in manufacturing lab

Our Pursuit of Progress


Alkermes' Head of Human Resources Steve Schiavo reflects on our employees' commitment during the COVID-19 pandemic.

Read More

Cancer Trials At-a-Glance


Learn more about our ongoing clinical development program for nemvaleukin alfa, our lead immuno-oncology candidate. The investigational IL-2 variant immunotherapy is currently being studied across

View Infographic

Portrait of employee standing in lab

Portrait of Craig Hopkinson in cafeteria

Unlocking IL-2's Potential


As the unmet medical need in oncology changes, Alkermes is using its R&D capabilities honed over 30 years of work on complex diseases to investigate a potential next breakthrough in cancer therapy.

Read the Scrip article

Media Resources

Company Description

Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.

Media Inquiries

Email our media team


Company Logos

Download


Company Photo

Download


Corporate Fact Sheet

Download


Follow us on our social channels   

blue triangle graphic

Statements and Positions

The idea that a corporation can play a profoundly positive role in society is central to our vision. It is our obligation to voice our beliefs about issues that impact the patients we serve, the communities in which we live and work and society at large.

Company Statement on the Invasion of Ukraine

Read our statement

Company Response to Board Nominations


Read our statement

Systemic Racism and Violence


Read our statement

Company Response to COVID-19


Read our response